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Introduction: Sex steroids are regulating factors for intrauterine growth. 17-β Estradiol
(E2) is particularly critical to a physiological pregnancy, as increased maternal E2 was
correlated to lower fetal weight at delivery. The placenta itself is a primary source
of estrogens, synthetized from cholesterol precursors. Cytochrome P450 aromatase
(encoded by CYP19A1 gene) is a rate-limiting enzyme for E2 biosynthesis. CYP19A1
transcription is supported by Estrogen Related-Receptor Gamma (ERRγ- ESRRG gene),
which thus has an indirect role in placental steroidogenesis. Here we investigated
maternal E2 levels and placental CYP19A1 and ESRRG expressions in pregnancies with
IntraUterine Growth Restriction (IUGR).
Methods: Singleton pregnancies were studied. E2 was measured in maternal plasma
by electrochemiluminescence in 16 term controls and 11 IUGR (classified by umbilical
artery doppler pulsatility index) at elective cesarean section, and also in 13 controls during
pregnancy at a gestational age comparable to IUGR. CYP19A1 and ESRRG expressions
were analyzed in placental tissue. Maternal/fetal characteristics, placental and molecular
data were compared among study groups and tested for correlations.
Results: Maternal E2 plasma concentrations were significantly decreased in IUGR
compared to controls at delivery. When analyzing normal pregnancies at a gestational
age similar to IUGR, E2 levels were not different to pathological cases. However, E2
levels at delivery positively correlated with placental efficiency. Placental CYP19A1 levels
were significantly higher in IUGR placental tissue vs. controls, and specifically increased
in female IUGR placentas. ESRRG expression was not different among groups.
Discussion: We report a positive correlation between 17-β Estradiol levels and
placental efficiency, that might indicate a disrupted steroidogenesis in IUGR pregnancies.
Moreover, we show alterations of CYP19A1 expression in IUGR placentas, possibly
indicating a compensatory effect to the adverse IUGR intrauterine environment, also
depending on fetal sex. Further studies are needed to deeper investigate IUGR alterations
in the complex interaction among molecules involved in placental steroidogenesis.
Keywords: intrauterine growth restriction, placenta, 17-β estradiol, estrogen-related receptor γ, cytochrome p450
aromatase
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HIGHLIGHTS
- Altered E2 levels suggest disturbances of estrogenic pathways in
IUGR pregnancies.
- ESRRG and CYP19A1 alterations may be linked to growth-
restriction features.
- CYP19A1 alteration as a clue of IUGR disrupted
placental steroidogenesis.
- Fetal sexmay influenceCYP19A1 expression in IUGR placentas.
INTRODUCTION
During pregnancy, a well-functioning placenta is needed to
ensure the appropriate growth and development of the fetus
(1). Indeed, an “insufficient” placenta is one of the main
characteristics of IntraUterine Growth Restriction (IUGR) (2),
with decreased oxygen supply and altered nutrient transport to
the fetus (3–7). Multiple stimuli occur throughout pregnancy
to achieve an appropriate placental vascularization, perfusion
and metabolism. Oxygen concentration, energy metabolism, and
sex steroids have been described as limiting factors for growth-
restriction onset (8–11).
Sex steroids in the fetal and maternal circulations play
an important role in determining a physiological placental
phenotype (12). Being a developing organ, the placenta
undergoes significant anatomical, and functional changes which
are partially regulated by steroids, particularly estrogens (13).
Indeed, inhibition of estrogen production was reported to
result in pregnancy loss in animal models (14, 15). Like other
estrogens, 17-β Estradiol (E2) is involved in each pregnancy
stage: it promotes endometrium growth, preparing the uterus for
embryo’s implantation, it regulates uterine vascular adaptations
to pregnancy and labor induction (16, 17), and is also critical
for trophoblast syncytialization (18). In early pregnancy, high
maternal estradiol levels have been reported to correlate with
increased risks of low neonatal weight (19), by affecting the
expression of CDKN1C and IGF2, placental imprinted-genes
which are relevant to fetal growth (20).
Growing evidence has been reported on the association
between altered circulating progesterone and estrogen
levels and PreEclampsia (PE) (21–23). Conversely, few
progesterone/estrogen profiles have been investigated in
pregnancies delivering Small for Gestational Age (SGA) babies.
First evidence that maternal 17-β Estradiol concentration may
be related to fetal growth restriction derived from a mid-to-late-
term pregnancy sheepmodel (24). Data from human pregnancies
were recorded by Salas et al. at 34 gestational weeks. Reduced
progesterone and estradiol plasma levels were measured in the
maternal plasma of women delivering SGA babies, but no clinical
data were reported about intrauterine growth (25).
During pregnancy, the placenta itself becomes the primary
source of progesterone (at term, 250 mg/day) and estrogens (at
term, 100–120 mg/day), synthetized from both maternal and
Abbreviations: CYP19A1, CYtochrome P450 aromatase gene; E2 or 17-β
Estradiol, 17-Beta Estradiol; ER, Estrogen Receptor; ESRRG, Estrogen Related-
Receptor Gamma gene; IUGR, Intrauterine Growth Restriction.
fetal cholesterol precursors. Indeed, sulfated C-19 androgens,
16α-hydroxylated DHEA-S and DHEA-S are processed into
estrogens by the activity of several enzymes involved in steroids
biosynthesis (known as steroidogenesis), namely placental
STeroid Sulfatase (STS), 3β HydroSteroid Dehydrogenases 1
(HSD1), CYP19 (CYtochrome P450 aromatase), and 17βHSD
isoenzymes. Estrogens produced in the placenta are then released
into both maternal and fetal circulations (26, 27).
Therefore, several placental genes are involved in
steroidogenesis, being critical to sex steroids metabolism.
Their expression may thus represent a limiting factor to normal
placental development (28).
CYtochrome P450 aromatase, encoded by CYP19A1, is a rate-
limiting enzyme for sex steroids biosynthesis, particularly for
placental 17-β Estradiol. Altered CYP19A1 gene and protein
levels have been recently observed in preeclamptic placentas,
associated with a trend to lower estriol and estradiol maternal
plasma profiling. Berkane et al. suggested placental hypoxia as
a possible causative mechanism for CYP19 dysregulation (29).
The consequent downregulation of E2 levels could contribute
to the antiangiogenic and vasoconstricted clinical features
of PE.
Among the Estrogen Receptors (ER) regulating sex steroids
metabolism, Estrogen Related-Receptor (ERR) is becoming
a promising topic of interest. ERR is involved in several
energetic pathways such as mitochondria replication and
Oxidative Phosphorylation (OXPHOS) (30), but is also a critical
mediator of multiple metabolic and endocrine signals (31, 32).
Its Gamma isoform (ESRRG) is predominantly expressed in
placenta (33), and regulates trophoblast differentiation. In vitro
studies have highlighted an oxygen-dependent expression for
ESRRG, being down-regulated in cytotrophoblast cultures under
hypoxia (34, 35).
ESRRG role in regulating placental steroidogenesis (36) has
been recently proposed by an in vitromodel reporting its binding
to CYP19A1 promoter (35), with the consequent induction
of Cytochrome p450 aromatase (37). Moreover, silencing of
ESRRG in extravillous trophoblasts has been recently reported
to suppress the expression of HSD17β1, another steroidogenic
enzyme critical to the placental conversion of estrone to
estradiol (38).
Here we hypothesize alterations of placental steroidogenesis
in IUGR compared to normal pregnancies. We measured
ESRRG and CYP19A1 gene expression in human IUGR
and control pregnancies, in both placental tissue and
isolated trophoblast cells, also in relation to IUGR
severity. Additionally, we analyzed 17-Beta Estradiol
levels in maternal plasma of the same pregnancies to
evaluate a potential cause-effect relation with ESRRG and
CYP19A1 expression.
METHODS
Pregnant women were enrolled in the Unit of Obstetrics
and Gynecology of the “Luigi Sacco Hospital” in Milano.
The study protocol was approved by the “L. Sacco Hospital”
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Ethical Committee and all participants gave their written
informed consent.
Population
Only Caucasian women with singleton spontaneous pregnancies
were included in the study. Exclusion criteria were maternal
preexisting diseases, alcohol or drug-abuse, maternal and fetal
infections, fetal malformations or chromosomal disorders.
Controls (n = 17) were term (≥37 weeks) physiological
pregnancies with normal intrauterine growth and Appropriate
for Gestational Age (AGA) birth weight, according to reference
ranges for the Italian population, and delivering by elective
cesarean section (CS) [Controls atDelivery]; no placental or fetal
disease were recorded. Indications for cesarean delivery before
labor were breech presentation, repeated cesarean sections, or
maternal request.
IntraUterine Growth Restriction [IUGR] pregnancies (n =
17) were identified in utero through longitudinal measurements
indicating abdominal circumferences below the 10th percentile of
age-related reference values (39) together with a shift from the
growth curve >40 centiles (40). IUGR were further evaluated
according to umbilical artery Pulsatility Index (PI) (measured
by doppler velocimetry) (5, 41) to be classified in two different
groups of severity [Normal PI IUGR or Abnormal PI IUGR].
All IUGR babies were delivered by elective cesarean section.
A further control group (n = 13) was enrolled during the
III trimester of normal pregnancy (26−32 weeks) to collect
maternal plasma samples with a gestational age similar to IUGR,
with confirmed AGA birth weight at the time of delivery [III
Trimester Controls].
Clinical Data Collection
Medical history, demographic, anthropometric, obstetric, and
neonatal data were recorded at recruitment and after delivery.
Maternal hemoglobin and hematocrit were measured at 34–
36 weeks.
Placental biometry parameters were measured and derived as
previously described (42).
Biological Samples Collection and
Analyses
17-Beta Estradiol Analysis in Maternal Plasma
Maternal blood was collected from a radial vein at III trimester
(n = 13) or at CS for AGA (n = 16) and IUGR (n = 11)
pregnancies. EDTA blood samples were centrifuged at 1500
rpm × 15min at room temperature and the obtained plasma
stored at−80◦C. Hemolyzed, icteric, and lipemic plasma samples
were excluded.
17-Beta Estradiol concentration was determined using an
electrochemiluminescence immunoassay (Estradiol G3 Elecsys
Cobas E100, ref. 06656021190) performed on Cobas e411
analyzer, according to themanufacturer’s instructions. All plasma
samples were diluted 1:10 and analyzed in duplicate; the
measurement interval was 549.8–4946 pg/mL. Internal quality
controls U1 and U2 (PreciControl Universal, ref. 11731416) were
concurrently analyzed with values within the expected ranges. E2
lower limit of detection was 5 pg/mL, while the intra and inter
assay coefficients of variation were both ≤10%.
All reagents and instrument were from Roche Diagnostic
GmbH, Mannheim, Germany.
Tissue Processing, Cells Isolation, RNA Extraction
Placentas were collected and sampled immediately after CS as
previously reported (43). After removing the maternal decidua,
placental biopsies (∼1 cm3) were sized from different cotyledons
midway between the cord insertion and placental border. Minced
placental villi were washed in PBS to be stored at −20◦C in RNA
Later Solution (Sigma-Aldrich, St. Louis/MO, USA). From tissue
fragments preserved in RNA Later (90mg), RNA was extracted
with the RiboPure RNAPurification Kit (Ambion- ThermoFisher
Scientific, Austin/TX, USA).
Isolated RNA was then treated with DNase I (New
England Biolabs, Ipswich/MA, USA), to remove potentially
contaminating DNA; RNA concentrations were measured
by NanoDrop ND1000 spectrophotometer (NanoDrop
Technologies, Wilmington/DE, USA).
ESRRG and CYP19A1 Expression in Placental Tissue
Gene expression of ESRRG [Chr.1] and CYP19A1 [Chr.15] was
measured in placental tissue [14 Controls and 14 IUGR]. For
each sample, 1.6 µg of total RNA were reverse-transcribed with
High Capacity cDNA Reverse Transcription Kit; cDNA served as
template for quantitative Real Time PCR with TaqMan probes
for ESRRG [assay ID: Hs00976243_m1] and CYP19A1 [assay
ID: Hs00903413_m1]. All samples were reverse-transcribed in
duplicate; cDNA was run in triplicate.
Expression levels were calculated using GeNorm method (44)
relative to HPRT [assay ID: Hs99999909_m1] and YWHAZ
[assay ID: Hs00237047_m1], selected as placental housekeeping
genes (45).
All reagents were supplied by Life Technologies
(ThermoFisher Scientific, Foster City/CA, USA).
Statistical Analyses
Maternal and fetal clinical characteristics and molecular data
displayed a normal distribution (Kolmogorov-Smirnov test)
and were thus compared among study groups by One-way
ANalysis Of VAriance (ANOVA) or independent-samples t-test
in accordance to the homogeneity of variance (Levene’s test).
A Two-way between-groups ANOVA was conducted to
assess the impact of IUGR severity and fetal sex (independent
variables), as individual or joint effect, on placental genes
expression (dependent variables), and applied with the Levene’s
assumptions. For both ANOVAs, a Tukey’s HSD test was run as
post-hoc test.
Chi-square test was performed to compare fetal sex
frequencies among groups, applying Yates continuity correction.
Correlations between clinical/molecular data were assessed
using the Pearson product-moment correlation.
Correlations and comparisons between groups were
considered statistically significant when p< 0.05.
Statistical analyses were performed using SPSS (v.25.00, IBM
Statistics, Armonk/NY, USA).
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TABLE 1 | Maternal, placental, and fetal characteristics in the analyzed population.
Controls at Delivery[*]
n = 17
Normal PI IUGR
n = 8
Abnormal PI IUGR
n = 9
III Trimester Controls[†]
n = 13
MATERNAL DATA
Age, years 34.6 ± 5.5 35.9 ± 4.4† 34.0 ± 5.9 30.1 ± 4.0
Pregestational BMI, kg/m2 21.3 ± 3.0 21.5 ± 2.2 24.3 ± 4.2 21.4 ± 2.6
Maternal hematocrit, Htc 34.0 ± 1.5 35.7 ± 2.8 34.9 ± 1.7 36.7 ± 5.3
Maternal hemoglobin, Hb 11.3 ± 0.7 11.7 ± 1.1 11.1 ± 1.4 12.4 ± 1.5
FETAL AND PLACENTAL DATA
Gestational age at sampling, wks 39.2 ± 0.4 34.9 ± 3.6 32.6 ± 3.6 32.7 ± 2.5
Gestational age at delivery, wks 39.2 ± 0.4 34.9 ± 3.6***†† 32.6 ± 3.6***††† 39.6 ± 0.9
Fetal weight, g 3401 ± 330 1768 ± 648***††† 1501 ± 785***††† 3419 ± 379
Placental weight, g 457 ± 88 316 ± 129**† 243 ± 128 ***††† 471 ± 83
Placenta area, cm2 282.9 ± 66.1 189.6 ± 71.6*† 156.8 ± 64.7**†† 350.9 ± 16.7
Placenta thickness, cm 1.7 ± 0.6 1.5 ± 0.1 1.5 ± 0.4 1.4 ± 0.3
Data are presented as mean ± standard deviation.
Post hoc comparisons using the Tukey HSD test are made between IUGR groups vs. Controls at Delivery [*]: *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001; or vs. III Trimester Controls [
†
]:
†
p ≤
0.05,
††
p ≤ 0.01;
†††
p ≤ 0.001.
IUGR, Intrauterine Growth Restriction; PI, umbilical artery Pulsatility Index used to define IUGR severity; BMI, Body Mass Index.
FIGURE 1 | 17-Beta estradiol in maternal blood. (A) E2 comparison among IUGR with Abnormal and Normal umbilical artery Pulsatility Index- PI, Controls at III
Trimester and Controls at Delivery; data shown as Box Plots graphs. Statistical analysis by One-way between-groups ANOVA: ∗∗p ≤ 0.01 vs. Controls. (B) Significant
positive correlation between 17-Beta Estradiol levels and placental efficiency in Controls at Delivery (©), Normal PI ( ), and Abnormal PI ( ) IUGR. Statistical analysis
by Pearson product-moment correlation: r = 0.51/p = 0.01.
RESULTS
Characteristics of the Population
Table 1 presents clinical data in Controls and in IUGR of
different severity.
Maternal age and pregestational Body Mass Index (BMI) did
not differ among groups.
No remarkable differences in maternal hemoglobin and
hematocrit levels were reported.
As expected, gestational age was significantly different among
groups [F(2, 33) = 21.7, p < 0.001], being lower in growth-
restricted babies compared to Controls at Delivery. Fetal weight
[F(2, 33) = 43.7, p < 0.001], placental weight [F(2, 31) = 11.2, p
< 0.001], and placental area [F(2, 25) = 9.0, p ≤ 0.001] resulted
significantly different among groups at delivery, with post-hoc
test confirming lower fetal-placental parameters for IUGRs vs.
term controls. Placental efficiency, calculated at delivery as fetal-
placental weight ratio, was significantly decreased in growth-
restricted pregnancies [Normal PI IUGR: 5.6 ± 0.6; Abnormal
PI IUGR: 5.8 ± 1.0] compared to Controls at Delivery [8.1 ±
2.3] (Post-Hoc test: p < 0.05 and p < 0.01, respectively). No
significant differences were found in the distribution of male and
female neonates between IUGR and controls [Fetal Sex: χ2(1,
n= 34 )= 1.91; p= 0.17; phi= 0.30].
Maternal, fetal and placental parameters were similar at
delivery (t-test: ns) between the two control groups, as shown
in Table 1, thus confirming that III Trimester Controls were
physiological throughout pregnancy. Gestational age at sampling
of III Trimester Controls [32.7 ± 2.5 weeks] was similar to
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FIGURE 2 | ESRRG and CYP19A1 expression in placental tissue. (A) CYP19A1 and (B) ESRRG mRNA levels in IUGR with Abnormal or Normal umbilical artery
Pulsatility Index- PI and Controls at Delivery; relative mRNA levels derived according to geNorm method and data shown as Box Plots graphs. Statistical analysis by
One-way between-groups ANOVA: ∗p ≤ 0.05 vs. Controls at Delivery. (C) Significant positive correlation between ESRRG and CYP19A1 expression in Controls at
Delivery (©), Normal PI ( ), or Abnormal PI ( ) IUGR. Statistical analysis by Pearson product-moment correlation: r = 0.50/p ≤ 0.01.
both Normal and Abnormal PI IUGR’s [Normal PI: 35.0 ± 3.6;
Abnormal PI: 32.6± 3.6 weeks] as designed for 17-Beta Estradiol
experiments (Table 1).
17-Beta Estradiol in Maternal Blood
Maternal 17-Beta Estradiol levels (E2, pg/mL) were significantly
different among groups [F(3, 39) = 4.9, p = 0.01] with a large
effect size (Eta -η2- Squared = 0.50). Plasma E2 had a decreased
mean score in both IUGR groups [Normal PI IUGR: 15305.4
± 7211.1; Abnormal PI IUGR: 14171.3 ± 6828.7] and in III
Trimester Controls [14915.0 ± 5877.5] compared to Controls at
Delivery [25351.3 ± 10755.4] (p = 0.01; Figure 1A). Maternal
E2 concentration significantly correlated with gestational age at
sampling (r =+0.57/p< 0.01, data not shown).
Interestingly, E2 levels at delivery were also
significantly and positively correlated to placental efficiency
(r =+0.51/p= 0.01; Figure 1B).
ESRRG and CYP19A1 in Placental Tissue
A One-way ANOVA was performed to explore differences
in ESRRG and CYP19A1 tissue expressions among groups.
There was a statistically significant difference among groups in
CYP19A1 levels [F(2, 27) = 4.3, p = 0.02] with a large effect size
(η2 = 0.50). Specifically, post-hoc test showed that CYP19A1
levels were significantly increased in the most severe IUGR cases
compared to both Normal PI IUGR and Controls (p = 0.02;
Figure 2A) [Abnormal PI IUGR: 0.22 ± 0.11; Normal PI IUGR:
0.12± 0.06; Controls: 0.11± 0.08].
No significant differences were found for ESRRG gene
expression [Normal PI IUGR: 0.43 ± 0.22; Abnormal PI IUGR:
0.47 ± 0.19; Controls: 0.38 ± 0.14] (Figure 2B). However,
ESRRG placental levels significantly correlated to CYP19A1 (r =
+0.50/p= 0.01; Figure 2C).
Placental CYP19A1 Expression in Relation to Fetal
Sex
Two-way ANOVA showed a statistically significant interaction
effect between growth restriction and fetal sex on placental
CYP19A1 [F(2, 22) = 5.27, p=0.01] with a large effect size (Partial
η2 = 0.32). This suggests that the effect of IUGR on CYP19A1
levels might also depend on fetal sex.
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This evidence was confirmed when comparing IUGR and
Controls fetuses of the same sex: CYP19A1 levels were
significantly increased only in female fetuses when comparing
Abnormal PI IUGR [0.30 ± 0.10] to Normal PI IUGR [0.08 ±
0.05] (p = 0.01, data not shown) and to Controls at Delivery
[0.12 ± 0.04] (p = 0.03; Figure 3). Interestingly, CYP19A1 gene
expression was increased in female [0.30 ± 0.10] compared to
male [0.14 ± 0.05] fetuses in the Abnormal PI IUGR subgroup
(p= 0.03; Figure 3); no significant differences were found within
the other subgroups.
DISCUSSION
In the present study we measured 17-Beta Estradiol levels in the
maternal circulation, where it is mostly secreted after its placental
production (46). We observed a significant decreased plasma
concentration of E2 in IUGR pregnancies at third trimester.
Moreover, we found a significant correlation between levels of 17-
Beta Estradiol and placental efficiency, the ratio between fetal and
placental weight, a parameter that has been associated with short-
and long-term adverse outcomes (4, 47, 48). Since a growth-
restricted placenta is known to present reduced efficiency (4),
this might contribute to lower hormonal production, in a context
of dysfunctional enzymatic metabolism. However, in our study
17-Beta Estradiol levels were not significantly different in IUGR
maternal plasma compared to controls of similar gestational age.
In the next future, we aim to enlarge this study population to
verify the possible influence of gestational age on E2 levels.
However, previous studies have reported lower progesterone
and estradiol concentrations in maternal plasma of growth-
restricted pregnancies (25). Circulating estradiol levels have also
been associated with the appropriate development of uterine
artery diameters and blood flow at high-altitude (49), which are
strictly related to placental development and consequently to
fetal growth (50). Interestingly, 17-β Estradiol is also involved in
nutrient supply. Indeed, in the mammary epithelium E2 activates
the expression of SNAT2 (Sodium-coupled Neutral amino acid
Transporter 2) (51), an important transporter of neutral amino
acids that is vital for a correct placental/fetal development.
Altered SNAT2 placental levels were previously reported by our
group in IUGR placentas, its expression decreasing with growth-
restriction severity (6). This may suggest a link between 17-β
Estradiol and calorie restriction, a condition characterizing IUGR
pregnancies, that needs further elucidation.
We then investigated the placental expression of CYP19A1,
a gene involved in E2 production. CYP19A1 expression is
influenced by hypoxic conditions (34), while its activity
is inhibited by ROS in placenta (52). Our study revealed
significantly increased placental CYP19A1 expression in IUGR
pregnancies, which might represent a feedback signal aimed
at supporting the disrupted estradiol production pathway. In
a sheep model of hypoxia and oxidative stress, disturbances
in ovarian aromatases function have been related to growth-
restriction (24), supporting the hypothesis that alterations of
the oxidative environment can cause changes in enzymes
involved in steroidogenesis (53). Moreover, in a previous
FIGURE 3 | CYP19 aromatase in placental tissue according to fetal sex.
CYP19A1 expression comparisons between female ( ) and male ( )
placentas in Abnormal PI IUGR and Controls at Delivery. Statistical analysis by
Two-way between-groups ANOVA: ∗p < 0.05 Female Controls, or p < 0.05
Male IUGR vs. Female Abnormal PI IUGR.
study investigating preeclamptic women, defective placental
steroidogenesis has been proposed to explain altered steroidal
plasma profiles, with accumulation of aromatase precursor-
hormones (androstenedione and testosterone) opposite to
diminished aromatase-metabolites (estrone and 17-β-Estradiol)
(54). Our results support the hypothesis that CYP19A1 placental
changes can represent a compensatory response to the altered
pathway of E2 synthesis in the IUGR placenta.
The Two-way ANOVA analysis revealed a significant
combined effect of IUGR severity and fetal sex on CYP19A1
levels. Fetal sex-related perturbations have been increasingly
studied in preterm pregnancies with alternative findings (53,
55–57). Our results in IUGR placentas are consistent with
changes noticed by Sathishkumar et al. in preeclamptic placentas
(58). Interestingly, a sexual dimorphism has been reported
in a maternal calorie-restriction rat model, where only male
puppies showed a significant decrease of oxidative-stress plasma
biomarkers (59). This might contribute to a different oxidative
stress-related CYP19A1 regulation in female and male placentas
(60). Sex-specific steroids secretion or epigenetic sex-specific
modulations might also represent mechanisms explaining our
findings (61). Our preliminary findings of a placental sexual
dimorphism involving sex steroids metabolism need deeper
investigation in the next future.
In our study we also evaluated the Estrogen-Related Receptor
“gamma” isoform, ESRRG, predominantly expressed in placenta
(33) and indirectly linked to pregnancy estrogen pathways by
supporting the expression of cytochrome P450 aromatase, one
of the key enzymes for 17-Beta Estradiol placental production
(62). ESRRG expression, inhibited by hypoxia, is also reported
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to be crucial in regulating trophoblast differentiation (63) and
for placental vascularization and endocrine function (31, 34,
35). Although we found that ESRRG levels were significantly
correlated to CYP19A1, we did not find significant differences
in ESRRG levels among groups, therefore suggesting that further
mechanisms might be involved in CYP19A1 dysregulation in
IUGR placentas.
This study was aimed at investigating placental changes of
ESRRG and CYP19A1 gene expressions in IUGR pregnancies,
and their possible impact on maternal 17-Beta Estradiol plasma
levels. Endocrine alterations likely can contribute to the growth-
restricted phenotype. We therefore hypothesized alterations
of placental steroidogenesis in IUGR compared to normal
pregnancies. Our results partially support this hypothesis,
showing that CYP19A1 placental changes could represent a
compensatory response to the altered pathway of E2 synthesis in
the IUGR placenta.
Data presented in this study, together with other recently
reported evidences, represent a step forward for a deeper
comprehension of placental steroidogenesis in IUGR. However,
further molecular mechanisms could likely be involved,
given the complexity of placental steroidogenesis and the
multifactorial IUGR pathophysiology. The recent system biology
approach, combining clinical, placental, and functional data
simultaneously, will possibly gain insights into these complex
pathways (64).
Strengths and Limitations
A strength of this study are the strict inclusion and exclusion
criteria that we applied for IUGR recruitment. Indeed, growth-
restricted pregnancies were identified in utero through
longitudinal measurements (abdominal circumferences
<10th percentile) and a shift from the growth curve >40
centiles. IUGR were further evaluated according to umbilical
artery pulsatility index being classified in two groups of
severity. This was a key point of this study, which allowed to
avoid several biases due to the IUGR multifactorial features.
However, the accurate selection of cases led to a limited
sample size.
Gestational age represents a limit in the comparison
between growth-restricted and control placentas. This is a limit
occurring in all studies investigating human IUGR pregnancies,
that cannot be avoided when studying placental samples.
Therefore, results need to be evaluated taking into account
this limitation.
CONCLUSIONS
This study shows a relationship between 17-β Estradiol levels
and placental efficiency in a population of intrauterine growth-
restricted pregnancies. Changes in 17-β Estradiol are associated
with a compensatory upregulation of CYP19A1 or CYtochrome
P450, an aromatase involved in E2 production. 17-β Estradiol
and sex steroids are involved in pregnancy from implantation
to parturition. Their biosynthesis and metabolism depend
on complex pathways involving the fetus, the placenta and
the mother. Additionally, we demonstrated a placental sexual
dimorphism with effect on these pathways. Further investigation
is needed to better understand the mechanisms behind the
alterations we reported in the present preliminary study, in
order to elucidate the pathophysiological strategies occurring
in IUGR.
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